SEARCH

SEARCH BY CITATION

References

  • 1
    Rosenwald A,Wright G,Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185197.
  • 2
    O'Connor OA,Wright J,Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676684.
  • 3
    Fisher RI,Bernstein SH,Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 48674874.
  • 4
    Belch A,Kouroukis CT,Crump M, et al. A Phase II study of bortezomib in patients with mantle cell lymphoma. Blood 2004; 104: 608a.
  • 5
    Drach J,Kaufmann H,Pichelmayer O, et al. Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma. Blood 2006; 108: 2753a.
  • 6
    Witzig T,Ansell S,Geyer S. Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle cell lymphoma: A Phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 6504a.
  • 7
    Witzig TE,Geyer SM,Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 53475356.
  • 8
    Ghielmini M,Schmitz SF,Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705711.
  • 9
    Foran JM,Cunningham D,Coiffier B, et al. Treatment of mantle cell lymphoma with rituximab (chimeric anti-CD20 monoclonal antibody): Analysis of factors associated with response. Ann Oncol 2000; 11( Suppl 1): 117121.
  • 10
    Coiffier B,Haioun C,Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 19271932.
  • 11
    Nguyen DT,Amess JA,Doughty H, et al. IDCE-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 1999; 62: 7682.
  • 12
    Lenz G,Dreyling M,Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 19841992.
  • 13
    Romaguera JE,Fayad L,Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 70137023.
  • 14
    Forstpointner R,Dreyling M,Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 30643071.
  • 15
    Dreyling M,Forstpointner R,Gramatzki M, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2006; 24: 7502a.
  • 16
    Inwards DJ,Hillman DW,Fishkin PA, et al. Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL). Blood 2006; 108: 2746a.
  • 17
    William ME,Cohen P,Tulpule A, et al. A phase II, multicenter study of bendamustine HCL plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol 2006; 24: 7528a.
  • 18
    Rummel MJ,Al-Batran SE,Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 33833389.
  • 19
    Bauwens D,Maerevoet M,Michaux L, et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 2005; 131: 338340.
  • 20
    Vose J,Loberiza F,Bierman P, et al. Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (M-C) (± rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol 2006; 24: 7511a.
  • 21
    Hess G,Flohr T,Huber C, et al. Safety and feasibility of CHOP/rituximab induction treatment followed by high dose chemoradiotherapy and autologous PBSC transplantation in patients with previously untreated mantle cell or indolent B cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 31: 775782.
  • 22
    de Guibert S,Jaccard A,Bernard M, et al. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006; 91: 425426.
  • 23
    Thieblemont C,Antal D,Lacotte-Thierry L, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104: 14341441.
  • 24
    Naing A,Palmer J,Tsai N, et al. Impact of rituximab on outcome of autologous transplantation for mantle cell lymphoma. J Clin Oncol 2006; 24: 7555a.
  • 25
    Van't Veer MB,Notenboom A,McKenzie M, et al. First report of the HOVON 45: A phase II study with rituximab, high dose Ara-C and autologous stem cell transplantation in the primary treatment of mantle cell lymphoma. Blood 2006; 108: 2734a.
  • 26
    Cortelazzo S,Magni M,Pintimalli M, et al. Frontline high dose sequential chemotherapy with rituximab (R-HDS) and autologous stem cell transplantation induces high rates of complete response and prolonges survival in mantle cell lymphoma (MCL). Blood 2006; 108: 3045.
  • 27
    Gianni AM,Cortelazzo S,Magni M, et al. Rituximab: Enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002; 29( Suppl. 1): S10S13.
  • 28
    Belhadj K,Delfau-Larue MH,Elgnaoui T, et al. Efficiency of in vivo purgibg with rituximab prior to autologous peripheral blood progenitor cell transplantation in B cell non-Hodgkin's lymphoma: A single institution study. Ann Oncol 2004; 15: 504510.
  • 29
    Freedman AS,Neuberg D,Gribben JG, et al. High dose chemoradiotherapy and anti B cell monoclonal antibody purged autologous bone marrow transplantation in mantle cell lymphoma: No evidence for long term remission. J Clin Oncol 1998; 16: 1318.
  • 30
    Mangel J,Buckstein R,Imrie K, et al. Immunotherapy with rituximab following high dose therapy and autologous stem cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29( Suppl 2): 5669.
  • 31
    Brugger W,Hirsch J,Grunebach F, et al. Rituximab consolidation after high dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective multicenter phase II study. Ann Oncol 2004; 15: 16911698.
  • 32
    Grigg AP,Bashford J,Seymour JF, et al. Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review. Leuk Lymphoma 2005; 44: 851860.
  • 33
    Hicks L,Connors JM,Mangel J, et al. Autologous stem cell transplant with a rituximab pruge and maintenance vs. standard chemotherapy for mantle cell lymphoma: Extended follow-up of a matched pair analysis. Blood 2006; 108: 3051a.
  • 34
    Wang M,Oki Y,Pro B, et al. Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 2006; 108: 2714a.
  • 35
    Weigert O,Jurczak W,Von Schiling C, et al. Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of European MCL Network and the PLRG. J Clin Oncol 2006; 24: 7533a.
  • 36
    Smith MR,Chen H,Gordon L, et al. Phase II study of rituximab+CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). J Clin Oncol 2006; 24: 7503a.
  • 37
    Jurczak W,Giza A,Szostek M, et al. 90Y- Zevalin® (90Y-Ibritumomab Tiuxetan) radioimmunotherapy (RIT) consolidation for FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: Results from the PLRG upon completed enrollment. Blood 2006; 108: 2747a.
  • 38
    Zelenetz AD,Noy A,Pandit-laskar N, et al. Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. Clin Oncol 2006; 24: 7560a.
  • 39
    Youngs A,Pro B,Rodriguez MA. Activity of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 2005; 106: 2452a.
  • 40
    Krishnan A,Raubitschek A,Forman S J, et al. New transplant strategies utilizing radioimmunotherapy (RIT) based regimens to reduce relapse in high risk mantle cell lymphoma (MCL). Blood 2005; 106: 681a.
  • 41
    Nademanee A,Forman SJ,Molina A, et al. High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial. J Clin Oncol 2004; 22: 6504a.
  • 42
    Vanazzi A,Ferrucci P,Grana C, et al. High dose 90Yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: preliminary results of a phase I/II study. Clin Oncol 2006; 24: 7587a.
  • 43
    Gopal AK,Rajendran JG,Petersdorf SH, et al. High-dose chemo-radiotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 31583162.
  • 44
    Eric J,Arnold F. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004; 16: 106113.
  • 45
    Maris MB,Sandmaier BM,Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 35353542.
  • 46
    Morris E,Thomson K,Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 38653871.
  • 47
    Khouri IF,Lee MS,Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 44074412.
  • 48
    Avivi I,Canals C,Taghipour G, et al. Matched unrelated donor stem cell transplantation for relapsed or refractory mantle cell lymphoma. A retrospective analysis from the EBMT Lymphoma Working Party. Blood 2006; 108: 3123a.
  • 49
    Russell NH,Ryrne JL,Faulkner RD, et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 437441.
  • 50
    Hoogendoorn M,Wolbers JO,Smit WM, et al. Primary allogeneic T-cell responses against mantle cell lymphoma antign-presenting cells for adoptive immunotherapy after stem cell transplantation. Clin Cancer Res 2005; 11: 53105318.
  • 51
    Bendandi M,Gocke CD,Kobrin CB, et al. Complete molecular remission induced by patients-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 11711177.
  • 52
    Timmerman JM,Vose J,Kunkel SL, et al. A phase II study demonstrating recombinant idiotype vaccine elicits specific anti-idiotype immune responses in aggressive non-Hodgkin's lymphoma. Blood 2001; 98( Suppl 1): 341a.
  • 53
    Dessureault S,Alsarraj M,McCarthy S, et al. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res 2005; 125: 173181.
  • 54
    Holman P,Medina B,Corringham S, et al. Early and robust immune responses to immune responses to idiotype (Id) vaccination occur in mantle cell lymphoma (MCL) and indolent lymphoma patients following autologous stem cell transplantation (ASCT). Blood 2003; 102: 3345a.
  • 55
    Leonard JP,Vose J,Timmerman J, et al. Recombinant idiotype-KLH vaccination (MyVaxTM) following CHOP chemotherapy in mantle cell lymphoma. Blood 2003; 102: 105a.
  • 56
    Neelapu SS,Kwak LW,Kobrin CB, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005; 11: 986991.
  • 57
    Timmerman JM,Czerwinski DK,Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002; 99: 15171526.
  • 58
    Munger CM,Vose JM,Joshi SS. Dendritic cell-based therapy for mantle cell lymphoma. Int J Oncol 2006; 28: 13371343.
  • 59
    Damaj G,Lefrere F,Delarue R, et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003; 17: 19141915.
  • 60
    Kaufmann H,Raderer M,Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104: 22692271.
  • 61
    Wang M,Fayad L,Hagemeister F, et al. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 2007; 25: 8030a.
  • 62
    Leonard JP,Furman RR,Ruan J, et al. New development in immunotherapy for non-Hodgkin's lymphoma. Curr Oncol Rep 2005; 7: 364371.
  • 63
    Forero-Torres A,Furman RR,Rosenblatt JD, et al. A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a Phase I study. J Clin Oncol 2006; 24: 7534a.
  • 64
    Younes A,Fayad L,Pro B, et al. Safety and efficacy of heat shock protein-peptide96 complex (HSPPC-96) vaccine therapy in patients with relapsed or previously untreated low-grade non-Hodgkin's lymphoma. Blood 2003; 102: 898a.